Panacea Bio Chem

The evidence ledger: what the published record shows for each component

Every entry below was verified against PubMed (NCBI E-utilities) and ClinicalTrials.gov on 2026-09-08 and re-verified on 2026-09-10. The six components sit at six different evidence levels; one tier is not transferable to another.

What this does not establish. No published study of this six-component combination — or of any comparable multi-peptide blend, in any species — was identified in PubMed or ClinicalTrials.gov as of 2026-09-08. The evidence above is per-molecule, was produced at routes and doses that differ from this product, and combining six actives does not combine their evidence. A registered trial is not a completed trial; a completed trial is not posted results; posted results are not a marketing authorisation.

What the US FDA has said about all six actives

Every one of the six Cellurevit actives is named by the US Food and Drug Administration on its compounding bulk-substances risk page (page current as of 04/22/2026; re-read from the raw page HTML on 2026-09-08). Ipamorelin acetate appears in the agency's 503B category-2 table (added 29 September 2023); BPC-157, CJC-1295, GHK-Cu (for injectable routes of administration), Selank acetate (TP-7) and thymosin beta-4 fragment (LKKTETQ), also known as TB-500, appear in its nominated-but-withdrawn table. The agency's own risk sentences, verbatim:

• BPC-157: “Compounded drugs containing BPC-157 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization. FDA has identified no, or only limited, safety-related information for the proposed routes of administration.”
• CJC-1295: “Compounded drugs containing CJC-1295 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to for peptide-related impurities and API characterization. FDA has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction. Available clinical data are limited.”
• GHK-Cu (injectable): “Compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities. There are limited data in humans to inform safety-related considerations.”
• Thymosin beta-4, fragment (LKKTETQ) / TB-500: “Compounded drugs containing thymosin Beta-4, Fragment (LKKTETQ) may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation as well as peptide-related impurities. FDA has not identified any human exposure data drug products containing Thymosin Beta-4, Fragment.”
• Selank acetate (TP-7): “Compounded drugs containing selank acetate may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities. FDA lacks important information regarding any safety issues raised by selank acetate administered to humans.”
• Ipamorelin acetate: the agency states that it “may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation or peptide-related impurities”, that it “contains unnatural amino acids, which add to the complexity of peptide characterization”, and that “[a] study published in literature identified serious adverse events including death when ipamorelin was administered intravenously for improving gastric motility.”

These are US compounding-policy statements about bulk substances — not statements about Cellurevit, not statements about UK law, and not findings of harm; an agency saying it lacks information is describing an information gap. Source: fda.gov — Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks.

Terminology: the names you will see elsewhere, and the molecules behind them

A bridge from the vocabulary searchers and communities actually use to the proper names of the molecules. Community terms as observed in search results on 2026-09-08; proper names and FDA namings from the sources cited in the sections above.

The community vocabulary

The proper names

Near-name collisions. The “Cellu-” namespace is crowded: search results for this name surface unrelated near-name products (Cellvita, Cellu Peptide, Cellu Collagen Peptides — observed 2026-09-08). Cellurevit is a Panacea Bio Chem product; the near-names are not connected to it.

How you would verify a six-component blend

For a single peptide, a certificate of analysis (COA) starts with HPLC purity and mass-spectrometry identity. For six peptides co-formulated in one cartridge the bar is higher. A COA for a product like this would need to show:

• Identity, per component. Mass spectrometry for each of the six molecules, not HPLC alone — the category’s own quality-education pages make the point for single peptides: a peptide missing one residue can read about 99% pure on HPLC while being none of the intended molecule.
• Purity, per component. HPLC with the method named and the acceptance threshold stated.
• Assay, per component. Quantitative content against a reference standard — is 5 mg actually 5 mg.
• Separability. One analytical run that resolves and quantifies all six co-formulated components. No published example of this for a multi-peptide blend was located in the research behind this page (2026-09-08).
• Oxygen exclusion. Headspace oxygen measured at seal.
• Stability. Per-component assay and impurity profile at defined timepoints and stated storage conditions.
• Reconstitution quality. Time to a clear solution, free of particulates.

Cellurevit™'s composition is stated openly, with exact amounts per component — a stronger starting position than the ratio-only disclosure common in this category. The analytical dataset behind it is not published today; the criteria above are what such a publication would need to contain.

Trending in the field